1228763-95-8

1228763-95-8 structure

Name: Monalizumab
Chemical Name: Monalizumab
CAS Number: 1228763-95-8
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Cell Cycle/DNA Damage Checkpoint Kinase (Chk)
Create Date: 2022-08-13 09:06:22
Modify Date: 2024-01-06 12:42:39
Monalizumab is a first-in-class immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC)[1][2].

Name	Monalizumab

Description	Monalizumab is a first-in-class immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC)[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> IFNAR Signaling Pathways >> Cell Cycle/DNA Damage >> Checkpoint Kinase (Chk) Research Areas >> Inflammation/Immunology
References	[1]. Thorbald van Hall, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019 Oct 17;7(1):263. [2]. Christian Borel, et al. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2020 Sep 21;12(9):2691.

No Any Chemical & Physical Properties